BGB-A317-290-LTE1

Enrolling by invitation

Study of Tislelizumab and/or Pamiparib Containing Treatments in Participants With Advanced Malignancies

Beigene Study ID info

BGB-A317-290-LTE1

ClinicalTrials.gov ID info

EudraCT Number info

2019-002554-23

Study Overview

Sex: All

Age: 18 Years and older (Adult, Older Adult)

Accepts Healthy Volunteers? yes

No Study Documents

Locations

Study Overview

Sex: All

Age: 18 Years and older (Adult, Older Adult)

Accepts Healthy Volunteers? yes

No Study Documents